Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of ($8.25), $0.63 worse than the analyst estimate of ($7.62). Revenue for the quarter came in at $1.05 billion versus the consensus estimate of $1.04 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.